Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and progression‐free survival (PFS) with manageable safety compared with placebo plus pemetrexed‐platinum in patients with previously untreated metastatic nonsquamous non–small‐cell lung cancer (NSCLC) without EGFR/A...

Descripción completa

Detalles Bibliográficos
Autores principales: Horinouchi, Hidehito, Nogami, Naoyuki, Saka, Hideo, Nishio, Makoto, Tokito, Takaaki, Takahashi, Toshiaki, Kasahara, Kazuo, Hattori, Yoshihiro, Ichihara, Eiki, Adachi, Noriaki, Noguchi, Kazuo, Souza, Fabricio, Kurata, Takayasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353942/
https://www.ncbi.nlm.nih.gov/pubmed/34036692
http://dx.doi.org/10.1111/cas.14980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353942/
https://www.ncbi.nlm.nih.gov/pubmed/34036692
http://dx.doi.org/10.1111/cas.14980

Ejemplares similares